We describe the third of three vaccination trials of Panamanian Aotus monkeys with a recombinant blood-stage antigen derived from the malaria parasite Plasmodium falciparum. Immunization 
either SERA 1 and Freund's, SERA 1 and MF75.2, or MF75.2 alone and that had been challenged but did not develop a countable parasitemia were treated with a curative dose of mefloquine 100 days after parasite challenge and then rechallenged 40 days later. None of the five rechallenged monkeys that had originally received SERA 1 and Freund's developed a countable parasitemia. Only one of five rechallenged monkeys that originally received SERA 1 and MF75.2 developed a high countable parasitemia, while two animals developed a barely countable parasitemia. Four of the rechallenged monkeys that had originally received only MF75.2 developed a moderate to high countable parasitemia. The results indicate that vaccination with SERA 1 and either Freund's or MF75.2 adjuvant provides protection and vaccination with MF75.2 alone can provide a temporary protection unrelated to the induction of anti-SERA 1 or antimalarial antibodies.
We have examined the capability of parts of the Plasmodium falciparum parasite antigen SERA (3, 6, (11) (12) (13) to induce parasite-inhibitory antibodies (1, 2) and a protective immune response in Panamanian Aotus monkeys (8, 9) . In a previous trial, trial 1 (9) , we reported that approximately the N-terminal quarter of the molecule, SERA 1, and half of the molecule, -ySERA N, mixed with Freund's adjuvant could induce a protective immune response. In the accompanying report, trial 2 (8) , preliminary evidence showed that the MF75.2 adjuvant, when mixed with the SERA 1 portion (amino acids 24 to 294) of the complete SERA molecule (989 amino acids) (3), also induces a protective immune response to challenge with blood-stage parasites. We 
MATERIALS AND METHODS
Monkeys. Panamanian Aotus lemurinus lemurinus monkeys were maintained in the animal facility of the Gorgas Memorial Laboratory in Panama City, Panama (14) . Thirtytwo animals (adult males and females, weighing 637 to 1,306 g), some born in the laboratory and some caught in the wild, were without previous exposure to P. falciparum. The monkeys were not splenectomized. They were divided into four groups of eight each that were balanced for sex, size, and whether they were born in the laboratory or caught in the wild, animals were injected intramuscularly with antigen(s) or adjuvant or both. A nonsplenectomized, malariainfected monkey was used as the source of parasites for challenge infections.
Antigens. The recombinant SERA-derived antigen, SERA 1, was described previously (2) . SERA 1 was dissolved in a carrier solution of phosphate-buffered saline and 0.05% sodium dodecyl sulfate and mixed with an equal volume of an appropriate adjuvant.
Adjuvant. Freund's (complete or incomplete), MF59.2, and MF75.2 adjuvants were described previously (2, 8, 9) .
Immunization. Antigen with appropriate adjuvant was injected intramuscularly on days 0, 28, and 56 of the experiment. Each dose of antigen was in a final volume of 1.0 ml that contained 100 ,ug of SERA 1. Freund's complete or incomplete adjuvant and antigen was mixed immediately before a vaccination injection. The other antigen-adjuvant divided into two 0.5-ml portions and injected intramuscularly into two sites in one thigh of the monkey. The booster injections were in the alternate thigh. All animals were bled 7 days prior to the start of immunization, which was designated as day 0, and then prior to and after parasite challenge.
Parasites. P. falciparum Honduras I (7) was used for challenge. It was chosen because it had been passaged through splenectomized and then nonsplenectomized Aotus monkeys (10) until it produced a good parasitemia in the latter and because the SERA-derived antigen was encoded by the cloned Honduras I SERA gene.
Parasite challenge and rechallenge. Twenty-nine days after the second booster injection, each monkey was injected intravenously with 5 x 104 parasites as described previously (8, 9) . Parasitized erythrocytes taken from the same infected monkey that had a moderate and increasing parasitemia were used in the challenge to ensure parasite viability and the same parasite dose per animal. After challenge, the parasitemia was monitored daily by both thick and EarlePerez (4) films stained with Giemsa. We evaluated parasitemias as described previously (8, 9 (8, 9) with those in this trial would also provide a better sample on which to base the interpretation of the results. In Table 1 are listed the groups of monkeys (groups 1 to 4), their respective treatments with adjuvant or antigen or both, and a summary of the humoral anti-SERA 1 antibody titers as measured by ELISA 10 days prior to and 10 days after challenge infection with the Honduras I strain. The control ELISA titers were <10.
The data showing the development and course of infection monitored in all monkeys for 140 days after challenge are shown (Fig. 1) . The data are plotted on a daily basis as described in Materials and Methods. On day 100 all monkeys were treated with a single curative dose of mefloquine. In group 1 monkeys, immunized with SERA 1 plus Freund's adjuvant, patent parasitemia was seen at 15 to 34 days in five monkeys. Two monkeys had no patent parasitemia. One monkey had a patent parasitemia on day 7, which was similar to previous observations of the appearance of the initial patent parasitemias (8, 9 Another way to display the data to compare parasitemias, and therefore the monkey's ability to control parasite growth in the different groups, is to determine the cumulative parasitemia that developed in monkeys during the periods of countable parasitemia, the "parasite load" (8) . This was calculated for each monkey from the data in Fig. 1 , and the data are shown in Fig. 2 . The protection provided monkeys vaccinated with SERA 1 and either Freund's or MF75.2 adjuvant is consistent with results presented in trials 1 and 2 (8, 9) . The failure to achieve protection in monkeys vaccinated with SERA 1 plus MF59.2 is consistent with the results presented in trial 2 (8 Fig. 1 and are represented as black bars. The thick black bar below the baseline set at 103
indicates that no countable parasitemia was observed in that monkey. A number at the top of a bar represents the cumulative countable parasitemia that was < 1,000 per mm3. An " x " below the graph indicates the death of a monkey due to non-parasite-associated causes. The monkey designated by the x in the MF75.2 group died before a valid assesment of parasitemia could be made. The monkey's adjuvant and antigen exposure is noted below the baseline. FA, Freund's adjuvant; S1, SERA 1. The line beneath the bars that indicate no countable parasitemia denotes those monkeys that were to be rechallenged after mefloquine treatment (Fig. 3) possibility that a high level of nonspecific antimalarial antibodies were produced by monkeys in group 4 prior to or after parasite challenge. Using a preparation of total parasite antigen, which should also include some SERA 1, we measured the antiparasite antibodies by ELISA in all prevaccination, 10-day prechallenge, and 10-day postchallenge monkey sera. The results, in summary, showed the following: (i) none of the prevaccination sera had detectable antiparasite antibody titers (<10); (ii) monkeys that were immunized with SERA 1 and Freund's, SERA 1 and MF59.2, SERA 1 and MF75.2, and only MF75.2 had average 10-day prechallenge antiparasite antibody titers that were, respectively, 9,746, 1,199, 3,724, and <10; (iii) monkeys that were immunized with SERA 1 and Freund's, SERA 1 and MF59.2, SERA 1 and MF75.2, and only MF75.2 had average 10-day postchallenge antiparasite antibody titers that averaged, respectively, 11,026, 1,320, 3,479, and 90. These results do not support the possibility that the challenged monkeys receiving only MF75.2 could have been protected by a production of high levels of antimalarial antibody.
We next tested the hypothesis that monkeys that received only MF75.2 were only transiently protected against bloodstage challenge compared with monkeys that received MF75.2 plus SERA 1. Five monkeys from each of the groups (groups 1, 3, and 4) that had been vaccinated but had not developed a countable parasitemia within 100 days of the initial parasite challenge (Fig. 2, underlined parasites per mm3. Three of five of the rechallenged monkeys from group 4 (MF75.2) developed a cumulative parasitemia of >100,000, and one developed a cumulative parasitemia of about 3,000. We interpret these results to support the interpretation that MF75.2 alone had an unknown transient effect on parasite growth in the challenged monkeys and the monkeys immunized with SERA 1 plus MF75.2 were protected through the immunization with SERA 1 and exhibited a transient adjuvant effect.
DISCUSSION
In this report we show that the SERA 1 antigen mixed with either Freund's or MF75.2 adjuvant provides protection to most vaccinated monkeys as measured by either the strict criterion of the vaccinated animals not developing a countable parasitemia or the less strict criterion of the challenged animals developing a delayed and significantly reduced parasitemia. The interpretation becomes more clear when the cumulative results from the two previous vaccination trials we have conducted are compared with those of trial 3 (8, 9) . If one considers that vaccine-protected monkeys are only those that do not develop a countable parasitemia, then the following ratio of protected/total monkeys receiving a particular treatment in those cumulative results from trials 1, 2, and 3 has been: 0:3 naive control animals; 1:6 animals when only Freund's adjuvant was given; 9:14 when Freund's adjuvant plus SERA 1 was given; 7:11 when MF75.2 plus SERA 1 was given; and 1/11 when MF59.2 plus SERA 1 was given. Overall protection afforded by SERA 1 immunization is even better than the data suggest when some animals exhibiting a delayed onset of a countable parasitemia and a low countable parasitemia are considered among the protected animals. It is clear that unknown variables, which may include individual monkey susceptibility to infection or immune system responsiveness, may occasionally influence the results and so make the interpretation of some results difficult.
While the results strongly confirm that SERA 1 and the appropriate adjuvant are very protective, we have been perplexed by our observations that immunized monkeys often do not show a sterile immune response but may show a recurring low-grade infection, as determined by positive thick smears, seen over long periods. In naturally immune humans in areas of endemicity, there is often a persistent low-level parasitemia associated with a premunition type of immunity. The anti-SERA 1 or anti-ySERA N (9) antibodies are clearly capable of suppressing the blood-stage infection and holding it in check; however, their presence is often not sufficient to eradicate the organism. We have speculated that the balance being struck between the growth rate of the parasite and the antiparasite action of the immune system is influenced by physiological factors that would eventually be tilted in favor of the complete immune suppression of parasite infection as a result of the stimulation of either a more effective anti-SERA 1 antibody response or other antiparasite antibodies developed during the controlled lowgrade infection. Measurements of the anti-SERA 1 and anti-P. falciparum antibodies to trophozoite and schizont antigens had been done after challenge. We examined the anti-SERA 1 antibody titers in monkeys 10 days after the challenge infection (Table 1) , which was 20 days after the previous titer was measured ( (8) . The inability of the animals immunized with SERA 1 and different adjuvants to sustain or increase the levels of anti-SERA 1 antibody titers and to develop other antimalarial antibodies after the challenge infection may in part explain the chronic low-level infections and the delayed occurrences of countable parasitemias seen in vaccinated animals.
We suggest that these results strongly support the use of SERA antigen as a useful vaccine antigen and highlight the necessity of choosing an appropriate adjuvant to promote its use.
